Skip to content
2000
image of Advances in Immune Checkpoint Inhibitors for the Treatment of Non-Small-Cell Lung Cancer with Central Nervous System Metastases: A Review

Abstract

Central nervous system (CNS) metastasis represents a severe complication in patients with advanced non-small cell lung cancer (NSCLC), significantly impacting both quality of life and prognosis. Immune checkpoint inhibitor (ICI)-based regimens have emerged as promising therapeutic options for NSCLC patients lacking actionable genetic alterations. Large-scale clinical trials and real-world studies are progressing in this field. Increasing clinical evidence suggests that ICIs exhibit favorable efficacy and safety in treating NSCLC with CNS metastasis, particularly showing enhanced activity in patients with high programmed death-ligand 1(PD-L1) expression levels (≥50%). This article aimed to review the therapeutic progress of ICI-based management of NSCLC with CNS involvement, covering systemic treatment strategies of ICIs combined with chemotherapy and multimodal treatment plans combining ICIs with radiotherapy and chemotherapy. By summarizing the results of existing large-scale clinical studies, the goal was to provide a phased summary for the clinical treatment of advanced NSCLC with CNS metastasis and propose ideas for future research directions.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096375189250923070038
2025-10-08
2025-12-24

  • From This Site

    /content/journals/ccdt/10.2174/0115680096375189250923070038
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Barnholtz-Sloan J.S. Sloan A.E. Davis F.G. Vigneau F.D. Lai P. Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 2004 22 14 2865 2872 10.1200/JCO.2004.12.149 15254054
    [Google Scholar]
  2. Stelzer K. Epidemiology and prognosis of brain metastases. Surg. Neurol. Int. 2013 4 5 192.(Suppl. 4) 10.4103/2152‑7806.111296 23717790
    [Google Scholar]
  3. Cheng H. Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018 19 1 e43 e55 10.1016/S1470‑2045(17)30689‑7 29304362
    [Google Scholar]
  4. Park J.H. Kim Y.J. Lee J.O. Lee K.W. Kim J.H. Bang S.M. Chung J.H. Kim J.S. Lee J.S. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012 76 3 387 392 10.1016/j.lungcan.2011.11.022 22186628
    [Google Scholar]
  5. Suh J.H. Kotecha R. Chao S.T. Ahluwalia M.S. Sahgal A. Chang E.L. Current approaches to the management of brain metastases. Nat. Rev. Clin. Oncol. 2020 17 5 279 299 10.1038/s41571‑019‑0320‑3 32080373
    [Google Scholar]
  6. Remon J. Le Rhun E. Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treat. Rev. 2017 53 128 137 10.1016/j.ctrv.2016.12.006 28110254
    [Google Scholar]
  7. Xiao G. Liu Z. Gao X. Wang H. Peng H. Li J. Yang L. Duan H. Zhou R. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: From rationale to clinical application. Immunotherapy 2021 13 12 1031 1051 10.2217/imt‑2020‑0262 34231370
    [Google Scholar]
  8. Reck M. Rodríguez-Abreu D. Robinson A.G. Hui R. Cs szi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; O’Brien, M.; Rao, S.; Hotta, K.; Leiby, M.A.; Lubiniecki, G.M.; Shentu, Y.; Rangwala, R.; Brahmer, J.R. Pembrolizumab versus chemotherapy for PD-L1–Positive non–small-cell lung cancer. N. Engl. J. Med. 2016 375 19 1823 1833 10.1056/NEJMoa1606774 27718847
    [Google Scholar]
  9. West H. McCleod M. Hussein M. Morabito A. Rittmeyer A. Conter H.J. Kopp H.G. Daniel D. McCune S. Mekhail T. Zer A. Reinmuth N. Sadiq A. Sandler A. Lin W. Ochi Lohmann T. Archer V. Wang L. Kowanetz M. Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 20 7 924 937 10.1016/S1470‑2045(19)30167‑6 31122901
    [Google Scholar]
  10. Ready N.E. Audigier-Valette C. Goldman J.W. Felip E. Ciuleanu T.E. Rosario García Campelo M. Jao K. Barlesi F. Bordenave S. Rijavec E. Urban L. Aucoin J.S. Zannori C. Vermaelen K. Arén Frontera O. Curioni Fontecedro A. Sánchez-Gastaldo A. Juan-Vidal O. Linardou H. Poddubskaya E. Spigel D.R. Ahmed S. Maio M. Li S. Chang H. Fiore J. Acevedo A. Paz-Ares L. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. J. Immunother. Cancer 2023 11 2 e006127 10.1136/jitc‑2022‑006127 36725084
    [Google Scholar]
  11. Zhang M. Rodrigues A.J. Pollom E.L. Gibbs I.C. Soltys S.G. Hancock S.L. Neal J.W. Padda S.K. Ramchandran K.J. Wakelee H.A. Chang S.D. Lim M. Hayden Gephart M. Li G. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. J. Neurooncol. 2021 152 1 125 134 10.1007/s11060‑020‑03686‑3 33415659
    [Google Scholar]
  12. Ribas A. Wolchok J.D. Cancer immunotherapy using checkpoint blockade. Science 2018 359 6382 1350 1355 10.1126/science.aar4060 29567705
    [Google Scholar]
  13. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012 12 4 252 264 10.1038/nrc3239 22437870
    [Google Scholar]
  14. Sakuishi K. Apetoh L. Sullivan J.M. Blazar B.R. Kuchroo V.K. Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010 207 10 2187 2194 10.1084/jem.20100643 20819927
    [Google Scholar]
  15. Bae E.A. Seo H. Kim B.S. Choi J. Jeon I. Shin K.S. Koh C.H. Song B. Kim I.K. Min B.S. Han Y.D. Shin S.J. Kang C.Y. Activation of NKT cells in an anti-PD-1–resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T Cells. Cancer Res. 2018 78 18 5315 5326 10.1158/0008‑5472.CAN‑18‑0734 30012672
    [Google Scholar]
  16. Ettinger D.S. Wood D.E. Aisner D.L. Akerley W. Bauman J.R. Bharat A. Bruno D.S. Chang J.Y. Chirieac L.R. D’Amico T.A. DeCamp M. Dilling T.J. Dowell J. Gettinger S. Grotz T.E. Gubens M.A. Hegde A. Lackner R.P. Lanuti M. Lin J. Loo B.W. Lovly C.M. Maldonado F. Massarelli E. Morgensztern D. Ng T. Otterson G.A. Pacheco J.M. Patel S.P. Riely G.J. Riess J. Schild S.E. Shapiro T.A. Singh A.P. Stevenson J. Tam A. Tanvetyanon T. Yanagawa J. Yang S.C. Yau E. Gregory K. Hughes M. Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2022 20 5 497 530 10.6004/jnccn.2022.0025 35545176
    [Google Scholar]
  17. Gandhi L. Rodríguez-Abreu D. Gadgeel S. Esteban E. Felip E. De Angelis F. Domine M. Clingan P. Hochmair M.J. Powell S.F. Cheng S.Y.S. Bischoff H.G. Peled N. Grossi F. Jennens R.R. Reck M. Hui R. Garon E.B. Boyer M. Rubio-Viqueira B. Novello S. Kurata T. Gray J.E. Vida J. Wei Z. Yang J. Raftopoulos H. Pietanza M.C. Garassino M.C. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N. Engl. J. Med. 2018 378 22 2078 2092 10.1056/NEJMoa1801005 29658856
    [Google Scholar]
  18. Chen M. Wei L. Wang Q. Xie J. Xu K. Lv T. Song Y. Zhan P. Efficacy of different therapies for brain metastases of non-small cell lung cancer: A systematic review and meta-analysis. Transl. Lung Cancer Res. 2023 12 4 689 706 10.21037/tlcr‑22‑515 37197616
    [Google Scholar]
  19. Mansfield A.S. Herbst R.S. de Castro G. Hui R. Peled N. Kim D.W. Novello S. Satouchi M. Wu Y.L. Garon E.B. Reck M. Robinson A.G. Samkari A. Piperdi B. Ebiana V. Lin J. Mok T.S.K. Outcomes With Pembrolizumab monotherapy in patients with programmed death-ligand 1–Positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin. Res. Rep 2021 2 8 100205 10.1016/j.jtocrr.2021.100205 34590048
    [Google Scholar]
  20. Goldberg S.B. Schalper K.A. Gettinger S.N. Mahajan A. Herbst R.S. Chiang A.C. Lilenbaum R. Wilson F.H. Omay S.B. Yu J.B. Jilaveanu L. Tran T. Pavlik K. Rowen E. Gerrish H. Komlo A. Gupta R. Wyatt H. Ribeiro M. Kluger Y. Zhou G. Wei W. Chiang V.L. Kluger H.M. Pembrolizumab for management of patients with NSCLC and brain metastases: Long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020 21 5 655 663 10.1016/S1470‑2045(20)30111‑X 32251621
    [Google Scholar]
  21. Crinò L. Bronte G. Bidoli P. Cravero P. Minenza E. Cortesi E. Garassino M.C. Proto C. Cappuzzo F. Grossi F. Tonini G. Sarobba M.G. Pinotti G. Numico G. Samaritani R. Ciuffreda L. Frassoldati A. Bregni M. Santo A. Piantedosi F. Illiano A. De Marinis F. Tamberi S. Giannarelli D. Delmonte A. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2019 129 35 40 10.1016/j.lungcan.2018.12.025 30797489
    [Google Scholar]
  22. Mahashabde R.V. Bhatti S.A. Martin B.C. Painter J.T. Rodriguez A. Ying J. Li C. Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases. Transl. Lung Cancer Res. 2024 13 7 1620 1634 10.21037/tlcr‑24‑205 39118898
    [Google Scholar]
  23. Vogelbaum M.A. Brown P.D. Messersmith H. Brastianos P.K. Burri S. Cahill D. Dunn I.F. Gaspar L.E. Gatson N.T.N. Gondi V. Jordan J.T. Lassman A.B. Maues J. Mohile N. Redjal N. Stevens G. Sulman E. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J. Clin. Oncol. ••• 40 34932393
    [Google Scholar]
  24. Goldberg S.B. Gettinger S.N. Mahajan A. Chiang A.C. Herbst R.S. Sznol M. Tsiouris A.J. Cohen J. Vortmeyer A. Jilaveanu L. Yu J. Hegde U. Speaker S. Madura M. Ralabate A. Rivera A. Rowen E. Gerrish H. Yao X. Chiang V. Kluger H.M. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016 17 7 976 983 10.1016/S1470‑2045(16)30053‑5 27267608
    [Google Scholar]
  25. Sun L. Davis C.W. Hwang W-T. Jeffries S. Sulyok L.F. Marmarelis M.E. Singh A.P. Berman A.T. Feigenberg S.J. Levin W. Ciunci C.A. Bauml J.M. Cohen R.B. Langer C.J. Aggarwal C. Outcomes in patients with non–small-cell lung cancer with brain metastases treated with pembrolizumab-based therapy, clinical lung cancer. Clinical. Lung Cancer 2021 22 58 66 10.1016/j.cllc.2020.10.017
    [Google Scholar]
  26. Weber J.S. D’Angelo S.P. Minor D. Hodi F.S. Gutzmer R. Neyns B. Hoeller C. Khushalani N.I. Miller W.H. Lao C.D. Linette G.P. Thomas L. Lorigan P. Grossmann K.F. Hassel J.C. Maio M. Sznol M. Ascierto P.A. Mohr P. Chmielowski B. Bryce A. Svane I.M. Grob J.J. Krackhardt A.M. Horak C. Lambert A. Yang A.S. Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 16 4 375 384 10.1016/S1470‑2045(15)70076‑8 25795410
    [Google Scholar]
  27. Dudnik E. Yust-Katz S. Nechushtan H. Goldstein D.A. Zer A. Flex D. Siegal T. Peled N. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer 2016 98 114 117 10.1016/j.lungcan.2016.05.031 27393516
    [Google Scholar]
  28. Zhang G. Cheng R. Wang H. Zhang Y. Yan X. Li P. Zhang M. Zhang X. Yang J. Niu Y. Ma Z. Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: A retrospective cohort study. Cancer Immunol. Immunother. 2020 69 3 399 405 10.1007/s00262‑019‑02462‑1 31907567
    [Google Scholar]
  29. Gauvain C. Vauléon E. Chouaid C. Le Rhun E. Jabot L. Scherpereel A. Vinas F. Cortot A.B. Monnet I. Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases. Lung Cancer 2018 116 62 66 10.1016/j.lungcan.2017.12.008 29413052
    [Google Scholar]
  30. Gadgeel S.M. Lukas R.V. Goldschmidt J. Conkling P. Park K. Cortinovis D. de Marinis F. Rittmeyer A. Patel J.D. von Pawel J. O’Hear C. Lai C. Hu S. Ballinger M. Sandler A. Gandhi M. Fehrenbacher L. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer 2019 128 105 112 10.1016/j.lungcan.2018.12.017 30642441
    [Google Scholar]
  31. Spigel D.R. Chaft J.E. Gettinger S. Chao B.H. Dirix L. Schmid P. Chow L.Q.M. Hicks R.J. Leon L. Fredrickson J. Kowanetz M. Sandler A. Funke R. Rizvi N.A. FIR: Efficacy, Safety, and biomarker analysis of a phase ii open-label study of Atezolizumab in PD-L1–selected patients with NSCLC. J. Thorac. Oncol. 2018 13 11 1733 1742 10.1016/j.jtho.2018.05.004 29775807
    [Google Scholar]
  32. Skribek M. Rounis K. Makrakis D. Agelaki S. Mavroudis D. De Petris L. Ekman S. Tsakonas G. Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a ‘real-life’ setting. Cancers 2020 12 12 3707 10.3390/cancers12123707 33321730
    [Google Scholar]
  33. Kang S. Jeong H. Park J.E. Kim H.S. Kim Y-H. Lee D.H. Kim S-W. Lee J.C. Choi C.M. Yoon S. Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between Intra/extracranial response in non-small cell lung cancer patients with brain metastasis. J. Cancer Res. Clin. Oncol. 2022 149 4523 10.21203/rs.3.rs‑1499774/v1
    [Google Scholar]
  34. Rounis K. Skribek M. Makrakis D. De Petris L. Agelaki S. Ekman S. Tsakonas G. Correlation of clinical parameters with intracranial outcome in non-small cell lung cancer patients with brain metastases treated with Pd-1/Pd-L1 Inhibitors as Monotherapy. Cancers 2021 13 7 1562 10.3390/cancers13071562 33805335
    [Google Scholar]
  35. Lakhani N.J. Papadopoulos K.P. Johnson M.L. Park H. Wang D. Yap T.A. Dowlati A. Maki R.G. Ulahannan S. Lynce F. Kelly K. Williamson S. Malhotra J. Chen S. Gonzalez Ortiz A. Jankovic V. Paccaly A. Masinde S. Mani J. Lowy I. Gullo G. Sims T. Kroog G. First-in-Human dose-escalation study of fianlimab, an antilymphocyte activation gene-3 antibody, with cemiplimab in patients with advanced malignancies. Clin. Cancer Res. 2024 30 24 5601 5611 10.1158/1078‑0432.CCR‑23‑3883 39422598
    [Google Scholar]
  36. Kilickap S. Özgüro lu, M.; Sezer, A.; Gümü 351; M.; Bondarenko, I.; Gogishvili, M.; Turk, H.M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Sriuranpong, V.; Quek, R.G.W.; McIntyre, D.A.G.; He, X.; McGinniss, J.; Seebach, F.; Gullo, G.; Rietschel, P.; Pouliot, J.F. Cemiplimab monotherapy as first line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death ligand 1 50%. Cancer 2025 131 10 e35864 10.1002/cncr.35864 40323717
    [Google Scholar]
  37. Zhao H. Huang S. Wu J. Lu Y. Zou Y. Zeng H. Li C. Wang J. Zhang X. Duan S. Liang W. Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: A systemic review and meta-analysis. Front. Immunol. 2025 16 1515027 10.3389/fimmu.2025.1515027 39981238
    [Google Scholar]
  38. Cheng W. Kang K. Zhao A. Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. J. Hematol. Oncol. 2024 17 1 54 10.1186/s13045‑024‑01581‑2 39068460
    [Google Scholar]
  39. Catalano M. Shabani S. Venturini J. Ottanelli C. Voltolini L. Roviello G. Lung cancer immunotherapy: Beyond common immune checkpoints inhibitors. Cancers 2022 14 24 6145 10.3390/cancers14246145 36551630
    [Google Scholar]
  40. Reck M. Ciuleanu T.E. Lee J.S. Schenker M. Zurawski B. Kim S.W. Mahave M. Alexandru A. Peters S. Pluzanski A. Caro R.B. Linardou H. Burgers J.A. Nishio M. Martinez-Marti A. Azuma K. Axelrod R. Paz-Ares L.G. Ramalingam S.S. Borghaei H. O’Byrne K.J. Li L. Bushong J. Gupta R.G. Grootendorst D.J. Eccles L.J. Brahmer J.R. Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 Part 1. J. Thorac. Oncol. 2023 18 8 1055 1069 10.1016/j.jtho.2023.04.021 37146754
    [Google Scholar]
  41. Mi Z. Zhang Y. Feng Z. Liu J. Wu J. Tan H. Ma X. Liu Z. Rong P. Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: A meta-analysis. Artif. Cells Nanomed. Biotechnol. 2022 50 1 301 309 10.1080/21691401.2022.2131354 36217590
    [Google Scholar]
  42. De Velasco G. Je Y. Bossé D. Awad M.M. Ott P.A. Moreira R.B. Schutz F. Bellmunt J. Sonpavde G.P. Hodi F.S. Choueiri T.K. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol. Res. 2017 5 4 312 318 10.1158/2326‑6066.CIR‑16‑0237 28246107
    [Google Scholar]
  43. Hendriks L.E.L. Henon C. Auclin E. Mezquita L. Ferrara R. Audigier-Valette C. Mazieres J. Lefebvre C. Rabeau A. Le Moulec S. Cousin S. Duchemann B. le Pechoux C. Botticella A. Ammari S. Gazzah A. Caramella C. Adam J. Lechapt E. Planchard D. De Ruysscher D. Dingemans A.M. Besse B. Outcome of patients with non–small cell lung cancer and brain metastases treated with checkpoint inhibitors. J. Thorac. Oncol. 2019 14 7 1244 1254 10.1016/j.jtho.2019.02.009 30780002
    [Google Scholar]
  44. Yang X. Zeng Y. Tan Q. Huang Z. Jia J. Jiang G. Efficacy of PD-1/PD-L1 inhibitors versus chemotherapy in lung cancer with brain metastases: A systematic review and meta-analysis. J. Immunol. Res. 2022 2022 1 14 10.1155/2022/4518898 35637793
    [Google Scholar]
  45. Powell S.F. Rodríguez-Abreu D. Langer C.J. Tafreshi A. Paz-Ares L. Kopp H.G. Rodríguez-Cid J. Kowalski D.M. Cheng Y. Kurata T. Awad M.M. Lin J. Zhao B. Pietanza M.C. Piperdi B. Garassino M.C. Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with nsclc and stable brain metastases: Pooled analysis of KEYNOTE-021, -189, and -407. J. Thorac. Oncol. 2021 16 11 1883 1892 10.1016/j.jtho.2021.06.020 34265431
    [Google Scholar]
  46. Gadgeel S. Rodríguez-Abreu D. Speranza G. Esteban E. Felip E. Dómine M. Hui R. Hochmair M.J. Clingan P. Powell S.F. Cheng S.Y.S. Bischoff H.G. Peled N. Grossi F. Jennens R.R. Reck M. Garon E.B. Novello S. Rubio-Viqueira B. Boyer M. Kurata T. Gray J.E. Yang J. Bas T. Pietanza M.C. Garassino M.C. Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer. J. Clin. Oncol. 2020 38 14 1505 1517 10.1200/JCO.19.03136 32150489
    [Google Scholar]
  47. Reck M. Ciuleanu T.E. Cobo M. Schenker M. Zurawski B. Menezes J. Richardet E. Bennouna J. Felip E. Juan-Vidal O. Alexandru A. Sakai H. Lingua A. Reyes F. Souquet P.J. De Marchi P. Martin C. Pérol M. Scherpereel A. Lu S. Paz-Ares L. Carbone D.P. Memaj A. Marimuthu S. Zhang X. Tran P. John T. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open 2021 6 5 100273 10.1016/j.esmoop.2021.100273 34607285
    [Google Scholar]
  48. Nadal E. Rodríguez-Abreu D. Simó M. Massutí B. Juan O. Huidobro G. López R. De Castro J. Estival A. Mosquera J. Sullivan I. Felip E. Blasco A. Guirado M. Pereira E. Vilariño N. Navarro V. Bruna J. Phase I.I. Phase I.I. Trial of Atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non–small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17/05). J. Clin. Oncol. 2023 41 28 4478 4485 10.1200/JCO.22.02561 37603816
    [Google Scholar]
  49. Zhou C. Wang Z. Sun M. Cao L. Ma Z. Wu R. Yu Y. Yao W. Sun S. Chen J. Zhuang W. Cui J. Chen X. Lu Y. Shen H. Hu C. Liu J. Liu Y. Wang M. Li X. Sun P. Shu Y. Zhou J. Li J. Gu K. Wang C. Zhao H. Zhang Y. Liu C. Wang J. Chen R. Qin M. Wang H. Yang J. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. Nat. Can. 2023 4 6 860 871 10.1038/s43018‑023‑00578‑z 37322367
    [Google Scholar]
  50. Dafni U. Tsourti Z. Vervita K. Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer 2019 134 127 140 10.1016/j.lungcan.2019.05.029 31319971
    [Google Scholar]
  51. Zhou C. Chen G. Huang Y. Zhou J. Lin L. Feng J. Wang Z. Shu Y. Shi J. Hu Y. Wang Q. Cheng Y. Wu F. Chen J. Lin X. Wang Y. Huang J. Cui J. Cao L. Liu Y. Zhang Y. Pan Y. Zhao J. Wang L. Chang J. Chen Q. Ren X. Zhang W. Fan Y. He Z. Fang J. Gu K. Dong X. Jin F. Gao H. An G. Ding C. Jiang X. Xiong J. Zhou X. Hu S. Lu P. Liu A. Guo S. Huang J. Zhu C. Zhao J. Gao B. Chen Y. Hu C. Zhang J. Zhang H. Zhao H. Wang Z. Ma X. Shi W. Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study. J. Immunother. Cancer 2024 12 11 e009240 10.1136/jitc‑2024‑009240 39608979
    [Google Scholar]
  52. Li Y.S. Yu Q. Bu Q. Lin L. Ning F. Zhao Y. Wu G. Lin G. Zang A. Sun H. Huang J. Tu H.Y. Ma S. Zhou C. Liu A. Wang C. Yao Y. Han G. Zhao J. Zhou Q. Yan H.H. Liu S.Y.M. Zheng M.M. Lv J. Cheng F. Chen Z. Zhong W.Z. Pan Y. Yang J.J. Wu Y.L. First-Line Camrelizumab versus placebo plus chemotherapy With or without radiotherapy for brain metastases in NSCLC: The CTONG 2003 randomized placebo-controlled trial. J. Thorac. Oncol. 2025 20 7 928 940 10.1016/j.jtho.2025.02.004 39929333
    [Google Scholar]
  53. Xu Y. Chen K. Xu Y. Li H. Huang Z. Lu H. Huang D. Yu S. Han N. Gong L. Qin J. Chen J. Xie F. Hong W. Lin X. Cheng F. Luo X. Fan Y. Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025 26 1 74 84 10.1016/S1470‑2045(24)00643‑0 39756446
    [Google Scholar]
  54. Hendriks L.E.L. Bootsma G. Mourlanette J. Henon C. Mezquita L. Ferrara R. Audigier-Valette C. Mazieres J. Lefebvre C. Duchemann B. Cousin S. le Pechoux C. Botticella A. De Ruysscher D. Dingemans A.M.C. Besse B. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur. J. Cancer 2019 116 182 189 10.1016/j.ejca.2019.05.019 31203193
    [Google Scholar]
  55. Brastianos P.K. Lee E.Q. Cohen J.V. Tolaney S.M. Lin N.U. Wang N. Chukwueke U. White M.D. Nayyar N. Kim A. Alvarez-Breckenridge C. Krop I. Mahar M.K. Bertalan M.S. Shaw B. Mora J.L. Goss N. Subramanian M. Nayak L. Dietrich J. Forst D.A. Nahed B.V. Batchelor T.T. Shih H.A. Gerstner E.R. Moy B. Lawrence D. Giobbie-Hurder A. Carter S.L. Oh K. Cahill D.P. Sullivan R.J. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat. Med. 2020 26 8 1280 1284 10.1038/s41591‑020‑0918‑0 32483359
    [Google Scholar]
  56. Naidoo J. Schreck K.C. Fu W. Hu C. Carvajal-Gonzalez A. Connolly R.M. Santa-Maria C.A. Lipson E.J. Holdhoff M. Forde P.M. Douville C. Riemer J. Barnes A. Redmond K.J. Kleinberg L. Page B. Aygun N. Kinzler K.W. Papadopoulos N. Bettegowda C. Venkatesan A. Brahmer J.R. Grossman S.A. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J. Immunother. Cancer 2021 9 8 e002473 10.1136/jitc‑2021‑002473 34380662
    [Google Scholar]
  57. Brastianos P.K. Strickland M.R. Lee E.Q. Wang N. Cohen J.V. Chukwueke U. Forst D.A. Eichler A. Overmoyer B. Lin N.U. Chen W.Y. Bardia A. Juric D. Dagogo-Jack I. White M.D. Dietrich J. Nayyar N. Kim A.E. Alvarez-Breckenridge C. Mahar M. Mora J.L. Nahed B.V. Jones P.S. Shih H.A. Gerstner E.R. Giobbie-Hurder A. Carter S.L. Oh K. Cahill D.P. Sullivan R.J. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat. Commun. 2021 12 1 5954 10.1038/s41467‑021‑25859‑y 34642329
    [Google Scholar]
  58. Chen H. Yang S. Wang L. Wu Y. Wu Y. Ma S. He Z. Zhang C. Liu Y. Tang H. Dong H. Wang Q. High-dose Furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: A prospective real-world study. J. Thorac. Oncol. 2025 20 1 65 75 10.1016/j.jtho.2024.09.1385 39260521
    [Google Scholar]
  59. Zheng M.M. Tu H.Y. Yang J.J. Zhang X.C. Zhou Q. Xu C.R. Jiang B.Y. Yang X.N. Yang X.R. Deng J.Y. Yang M.Y. Xu B.F. Chen X.M. Li Y.S. Wu Y.L. Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. Eur. J. Cancer 2021 150 23 30 10.1016/j.ejca.2021.03.037 33882375
    [Google Scholar]
  60. Zhou F. Qiao M. Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell. Mol. Immunol. 2021 18 2 279 293 10.1038/s41423‑020‑00577‑5 33177696
    [Google Scholar]
  61. Ma Y. Zeng J. Ding F. Xu Y. Wang Y. Zhong G. Liu N. Wang Y. Li Y. Chen S. Wei X. Zhu P. Jian G. Niu Y.S. Fu G. Liu C. Li G. Zhou X. Zhang A. Weng S. Cerebral 18 F-FDG PET/CT metabolism as diagnostic signature for central nervous system toxicity after immune checkpoint blockade cancer treatment. J. Nucl. Med. 2024 65 7 1129 1136 10.2967/jnumed.123.267025 38697671
    [Google Scholar]
  62. El Rassy E. Botticella A. Kattan J. Le Péchoux C. Besse B. Hendriks L. Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. Cancer Treat. Rev. 2018 68 69 79 10.1016/j.ctrv.2018.05.015 29883857
    [Google Scholar]
  63. Vilariño N. Bruna J. Bosch-Barrera J. Valiente M. Nadal E. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Cancer Treat. Rev. 2020 89 102067 10.1016/j.ctrv.2020.102067 32682248
    [Google Scholar]
  64. Li J. Wang M. Xu S. Li Y. Li J. Yu J. Zhu H. The strategies and mechanisms of immune checkpoint inhibitors for brain metastases in NSCLC. Front. Pharmacol. 2022 13 841623 10.3389/fphar.2022.841623 35656295
    [Google Scholar]
  65. Camy F. Karpathiou G. Dumollard J.M. Magne N. Perrot J.L. Vassal F. Picot T. Mobarki M. Forest F. Casteillo F. Hathroubi S. Froudarakis M. Peoc’h M. Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status. J. Immunother. Cancer 2020 8 2 e000597 10.1136/jitc‑2020‑000597 32859740
    [Google Scholar]
  66. Ni J. Zhang Z. Ge M. Chen J. Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: An update and new insights. Acta Pharmacol. Sin. 2023 44 2 288 307 10.1038/s41401‑022‑00953‑z 35927312
    [Google Scholar]
  67. Peng J. Hamanishi J. Matsumura N. Abiko K. Murat K. Baba T. Yamaguchi K. Horikawa N. Hosoe Y. Murphy S.K. Konishi I. Mandai M. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor- B to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 2015 75 23 5034 5045 10.1158/0008‑5472.CAN‑14‑3098 26573793
    [Google Scholar]
  68. Bernstein M.B. Krishnan S. Hodge J.W. Chang J.Y. Immunotherapy and stereotactic ablative radiotherapy (ISABR): A curative approach? Nat. Rev. Clin. Oncol. 2016 13 8 516 524 10.1038/nrclinonc.2016.30 26951040
    [Google Scholar]
  69. Kudo Y. Haymaker C. Zhang J. Reuben A. Duose D.Y. Fujimoto J. Roy-Chowdhuri S. Solis Soto L.M. Dejima H. Parra E.R. Mino B. Abraham R. Ikeda N. Vaporcyan A. Gibbons D. Zhang J. Lang F.F. Luthra R. Lee J.J. Moran C. Huse J.T. Kadara H. Wistuba I.I. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann. Oncol. 2019 30 9 1521 1530 10.1093/annonc/mdz207 31282941
    [Google Scholar]
  70. Lehrer EJ Gurewitz J Bernstein K Kondziolka D Fakhoury KR Rusthoven CG Niranjan A Wei Z Lunsford LD Malouff TD Ruiz-Garcia H Peterson JL Bonney P Hwang L Yu C Zada G Deibert CP Prasad RN Raval RR Palmer JD Patel S Picozzi P Franzini A Attuati L Mathieu D Trudel C Lee CC Yang HC Jones BM Green S Ahluwalia MS Sheehan JP Trifiletti DM Concurrent administration of immune checkpoint inhibitors and stereotactic radiosurgery is well-tolerated in patients with melanoma brain metastases: An international multicenter study of 203 patients. Neurosurgery 2022 91 6 872 882 10.1227/neu.0000000000002127
    [Google Scholar]
  71. Qian J.M. Yu J.B. Kluger H.M. Chiang V.L.S. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 2016 122 19 3051 3058 10.1002/cncr.30138 27285122
    [Google Scholar]
  72. Tagliaferri L. Lancellotta V. Fionda B. Mangoni M. Casà C. Di Stefani A. Pagliara M.M. D’Aviero A. Schinzari G. Chiesa S. Mazzarella C. Manfrida S. Colloca G.F. Marazzi F. Morganti A.G. Blasi M.A. Peris K. Tortora G. Valentini V. Immunotherapy and radiotherapy in melanoma: A multidisciplinary comprehensive review. Hum. Vaccin. Immunother. 2022 18 3 1903827 10.1080/21645515.2021.1903827 33847208
    [Google Scholar]
  73. Candido W. Eggen A.C. Jalving M. Bosma I. Horinga R.D. van Heuvelen K.C. Hiltermann T.J.N. Oosting S. Racz E. van der Klauw M.M. Reyners A.K.L. Nuver J. Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment. J. Immunother. Cancer 2025 13 3 e011168 10.1136/jitc‑2024‑011168 40154959
    [Google Scholar]
  74. Park K. Özgüro lu, M.; Vansteenkiste, J.; Spigel, D.; Yang, J.C.H.; Ishii, H.; Garassino, M.; de Marinis, F.; Szczesna, A.; Polychronis, A.; Uslu, R.; Krzakowski, M.; Lee, J.S.; Calabrò, L.; Arén Frontera, O.; Xiong, H.; Bajars, M.; Ruisi, M.; Barlesi, F. Avelumab versus Docetaxel in patients with platinum-treated advanced NSCLC: 2-Year follow-up from the JAVELIN lung 200 phase 3 trial. J. Thorac. Oncol. 2021 16 8 1369 1378 10.1016/j.jtho.2021.03.009 33845211
    [Google Scholar]
  75. Özgüro lu, M; Kilickap, S; Sezer, A; Gümü 351; M; Bondarenko, I; Gogishvili, M; Nechaeva, M; Schenker, M; Cicin, I; Ho, GF; Kulyaba, Y; Zyuhal, K; Scheusan, RI; Garassino, MC; He, X; Kaul, M; Okoye, E; Li, Y; Li, S; Pouliot, JF; Seebach, F; Lowy, I; Gullo, G; Rietschel, P First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 24 9 989 1001 10.1016/S1470‑2045(23)00329‑7
    [Google Scholar]
  76. Paz-Ares L. Ciuleanu T.E. Cobo M. Schenker M. Zurawski B. Menezes J. Richardet E. Bennouna J. Felip E. Juan-Vidal O. Alexandru A. Sakai H. Lingua A. Salman P. Souquet P.J. De Marchi P. Martin C. Pérol M. Scherpereel A. Lu S. John T. Carbone D.P. Meadows-Shropshire S. Agrawal S. Oukessou A. Yan J. Reck M. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 22 2 198 211 10.1016/S1470‑2045(20)30641‑0 33476593
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096375189250923070038
Loading
Advances in Immune Checkpoint Inhibitors for the Treatment of Non-Small-Cell Lung Cancer with Central Nervous System Metastases: A Review
Bentham Science Publishers ; https://doi.org/10.2174/0115680096375189250923070038
/content/journals/ccdt/10.2174/0115680096375189250923070038
/content/journals/ccdt/10.2174/0115680096375189250923070038
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Central nervous system metastases ; brain metastases ; immunotherapy ; leptomeningeal metastases ; non-small cell lung cancer ; immune checkpoint inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test